Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced Yasmine Wasfi, M.D., Ph.D., FCCP has been promoted to CMO, effective immediately. She succeeds Ray Pratt, M.D., FACP who will transition from his current role to Senior Medical Advisor. Dr. Wasfi will report directly to the Company’s Chair and Chief Executive Officer and will serve as a member of the executive leadership team. Previously, Dr. Wasfi was Executive Vice President, Head of Clinical Development and Clinical Operations at Savara.
Health Technology Insights: Roquette Launches Pharma Innovation Center to Boost Latin America as Collaborative Hub
“We are pleased to promote Dr. Wasfi to CMO,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. “Dr. Wasfi is a pulmonologist with more than two decades of healthcare experience, spanning both biotech and large pharma. She has a strong track record progressing and driving the development strategy for investigational therapies within the respiratory and immunology therapeutic areas and her leadership and relentless commitment to the autoimmune pulmonary alveolar proteinosis, or autoimmune PAP, patient community has been instrumental in helping advance the MOLBREEVI* program. We appreciate Dr. Wasfi’s contributions to date and look forward to the insights and direction she will bring in her new role.”
Pauls continued, “Having contributed to many regulatory applications over the span of his 35 years in drug development, we are grateful to benefit from Dr. Pratt’s experience and thank him for his invaluable contributions in advancing the MOLBREEVI program. We are fortunate to continue with his guidance as a Senior Medical Advisor.”
Health Technology Insights: LegitScript Sees Record Growth in Global Digital Health Certification
“I’d like to congratulate Dr. Wasfi on her promotion,” said Ray Pratt, M.D., FACP, CMO, Savara. “She brings significant experience in biopharmaceuticals to this role and has already made important contributions to our clinical development and regulatory efforts. It’s been a privilege to lead the MOLBREEVI clinical program through numerous late-stage milestones as we work to bring the first and only approved therapy for autoimmune PAP to market in the U.S. and Europe. I look forward to continue supporting the Company in my role as Senior Medical Advisor.”
Dr. Wasfi is a seasoned professional within clinical research and drug development of both large and small molecule novel therapeutics. Her clinical development work includes respiratory drug development and late-phase immunology clinical development. Dr. Wasfi has held roles of increasing responsibility within large pharmaceutical and smaller biotech companies, including Amicus Therapeutics, Johnson & Johnson, and Merck. She received a B.A. in Biology from the University of Delaware, M.D. from the University of Pennsylvania School of Medicine, and Ph.D. in Clinical Science from the University of Colorado Health Sciences Center. She completed her internship and residency in internal medicine at the Hospital of the University of Pennsylvania, and her fellowship in Pulmonary and Critical Care at the University of Colorado Health Sciences Center.
Health Technology Insights: Trilliant Health Launches Oria AI for Price Transparency
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire